• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Coya Therapeutics, Inc. - Common Stock (NQ: COYA )

    5.950 +0.300 (+5.31%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Coya Therapeutics, Inc. - Common Stock

    < Previous 1 2 Next >
    COYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024
    COYA stock results show that Coya Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    7 Biotech Stocks to Put on Your Breakthrough Radar
    Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
    Via InvestorPlace
    EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
    Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD,... 
    Via Benzinga
    COYA Stock Earnings: Coya Therapeutics Misses EPS for Q1 2024
    COYA stock results show that Coya Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023
    Coya Therapeutics just reported results for the fourth quarter of 2023. 
    Via InvestorPlace
    Coya Therapeutics
    100% technical buy signals. 15 new highs and up 43.21% in the last month. 74.87+ Weighted Alpha 
    Via Talk Markets
    Analyst Expectations for Coya Therapeutics's Future
    Via Benzinga
    The Latest Analyst Ratings for Coya Therapeutics
    Via Benzinga
    Coya Therapeutics: Another Sucess
    The Coya story is just beginning and as the company expands with larger trials, the success in those trials will only increase the valuation of the company. 
    Via Talk Markets
    Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases
    Dr. Howard Burman, Ph.D, CEO and Dr. Arun Swaminathan, CBO, of Coya Therapeutics Inc (NASDAQ: COYA), were guests on Benzinga’s All Access. 
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    How The Same Treatments May Work For Multiple Neurodegenerative Diseases
    Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate. 
    Via Talk Markets
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Coya Therapeutics' Alzheimer's Candidate Shows Lower Biomarker Levels Associated With Neuroinflammation
    Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for low-dose interleukin 2 (ld IL-2) in patients  
    Via Benzinga
    Why Coya Therapeutics Shares Are Shooting Higher Today
    Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for COYA 301 in  
    Via Benzinga
    The Immunotherapy Market Is Expected To Surpass $351.56 Billion By 2030 – Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) Is Contributing to This Growth
    Immunotherapy, in general, is an exciting and growing sector in the pharmaceutical industry. It involves manipulating the human body's immune system to treat various diseases. While historically this... 
    Via Benzinga
    Marsh & McLennan To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
    Raymond James cut the price target for Brinker International, Inc. (NYSE: EAT) from $46 to $42.5. Raymond James analyst Brian Vaccaro maintained an Outperform rating. Brinker shares fell 6.3% to close... 
    Via Benzinga
    Blood Biomarker, Brain Imaging Data Shows Coya Therapeutics' Alzheimer's Candidate Lowers Neuroinflammation
    Coya Therapeutics Inc (NASDAQ: COYA) reported additional biomarker and brain imaging results from an open-label proof-of-concept study for COYA 301 for  
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket
    Gainers Visionary Education Technology Holdings Group Inc. (NASDAQ: VEDU) shares rose 85.8% to $0.7985 in pre-market trading. 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    It's time for another dive into the latest pre-market stock movers as we check out all of the news moving shares on Tuesday morning! 
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
    Via Benzinga
    Tesla, Manchester United, Ohmyhome, Target, Coya: Why These 5 Stocks Are Drawing Investor Attention Today
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Positive Financials Along With Promising Clinical Results – Coya Therapeutics
    Howard Berman, Ph.D., CEO & Chairman of the Board of Coya Therapeutics, Inc. (NASDAQ: COYA), was recently a guest on Benzinga’s All Access. 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
    Via Benzinga
    Coya Therapeutics: An Attractive Valuation And First Set Of Data
    Coya recent data in ALS seems under appreciated by the market and upcoming data in Alzheimer's offers the opportunity to confirm the early signals of efficacy in neurological conditions. 
    Via Talk Markets
    Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments — Could Regulatory T-Cells (Tregs) Be The Answer?
    In many ways, Alzheimer's disease (AD) remains a mystery. Most common in those over 65, AD is the most common form of dementia, but its exact causes remain unclear, and treatments are unable to halt or... 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.